{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:07Z","timestamp":1793320627692,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T00:00:00Z","timestamp":1535846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ygyno.2018.08.036","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T07:46:46Z","timestamp":1542354406000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer"],"prefix":"10.1016","volume":"152","author":[{"given":"Antonio","family":"Gonz\u00e1lez Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Embleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-7247","authenticated-orcid":false,"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique A.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8348","authenticated-orcid":false,"given":"Richard S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Perren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.08.036_bb0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0010","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 investigators., A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0020","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx066","article-title":"Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses","volume":"109","author":"Bais","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"suppl","key":"10.1016\/j.ygyno.2018.08.036_bb0035","first-page":"5s","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0040","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-16-2196","article-title":"Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes","volume":"23","author":"Kommoss","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0045","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-13-3248","article-title":"The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in bevacizumab-treated ovarian cancer patients","volume":"20","author":"Backen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0055","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ygyno.2013.04.139","article-title":"Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab","volume":"130","author":"Randall","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"Suppl","key":"10.1016\/j.ygyno.2018.08.036_bb0060","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: a NRG oncology\/Gynecologic Oncology Group (GOG) study","volume":"36","author":"Burger","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2018.08.036_bb0070","first-page":"S161","article-title":"Carcinoma of the ovary","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0075","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-07-1888","article-title":"Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?","volume":"14","author":"Duncan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/CEJ.0b013e3283552e28","article-title":"Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage","volume":"22","author":"Chen","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0085","first-page":"171","article-title":"Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer","volume":"32","author":"Wang","year":"2011","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/gyno.2001.6313","article-title":"Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with \u201cbiological aggressiveness\u201d and survival?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0095","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0110","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0125","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)","volume":"17","author":"Wimberger","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0130","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","article-title":"Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study","volume":"22","author":"Luyckx","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.036_bb0135","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0140","first-page":"731","article-title":"Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy","volume":"31","author":"Hata","year":"2011","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2018.08.036_bb0145","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2011.04.041","article-title":"The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study","volume":"122","author":"Hamilton","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0160","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.036_bb0165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.08.036_bb0170","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.036_bb0175","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IGC.0000000000000690","article-title":"Minimal macroscopic residual disease (0.1\u20131\u202fcm). Is it still a surgical goal in advanced ovarian cancer?","volume":"26","author":"Chiva","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.036_bb0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5468\/ogs.2015.58.2.124","article-title":"Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification","volume":"58","author":"Paik","year":"2015","journal-title":"Obstet. Gynecol. Sci."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:55:15Z","timestamp":1717214115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818311661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0090825818311661"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}